Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Pr... Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.23 | -12.5683060109 | 1.83 | 2.12 | 1.6 | 249635 | 1.97723002 | CS |
| 4 | -0.88 | -35.4838709677 | 2.48 | 2.52 | 1.3 | 350907 | 1.86386832 | CS |
| 12 | -4.34 | -73.063973064 | 5.94 | 8 | 1.3 | 191580 | 2.78716152 | CS |
| 26 | -6.42 | -80.0498753117 | 8.02 | 8.74 | 1.3 | 116181 | 3.69255476 | CS |
| 52 | -7.9 | -83.1578947368 | 9.5 | 10.29 | 1.3 | 113165 | 5.7299491 | CS |
| 156 | -12.29 | -88.4809215263 | 13.89 | 25.47 | 1.3 | 142253 | 8.67673601 | CS |
| 260 | -12.29 | -88.4809215263 | 13.89 | 25.47 | 1.3 | 142253 | 8.67673601 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
